

individual and compounded barriers on health outcomes along the CCC for survivors. CDC will use a mixed methods data collection and analysis approach. First, CDC will pull our sample from cancer registry data in California, North Carolina, and Texas based on inclusion criteria (received first cancer diagnosis of either breast, cervical or colorectal cancer in 2021; 21–75 years of age at time of diagnosis; are non-Hispanic Black/African American, non-Hispanic White, or

Hispanic; alive at the time of data extraction/sample selection). Then, CDC will administer a Wave 1 (baseline) and Wave 2 (one-year follow-up) survey to cancer survivors, as well as a survey to their caregivers. Additionally, CDC will conduct interviews with selected survivors and caregivers as well as focus groups with representatives from patient/survivor advocacy organizations.

CDC will incorporate cancer registry data into the quantitative data analysis,

and triangulate findings from the quantitative and qualitative data collection efforts. Results will be used to inform efforts aimed at increasing access to cancer care services, reducing the burden of cancers and closing the disparities gap. CDC requests OMB approval for an estimated 1,681 annual burden hours. There are no costs to respondents other than their time to participate.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Wave 1 Survivor Survey Respondents .....	W1 Survey Instrument .....	3,000	1	20/60
Wave 2 Survivor Survey Respondents .....	W2 Survey Instrument .....	1,200	1	20/60
Survivor Interviewees .....	Survivor Interview Guide .....	20	1	1
Caregiver Survey Respondents .....	Caregiver Survey Instrument .....	900	1	15/60
Caregiver Interviewees .....	Caregiver Interview Guide .....	20	1	1
Patient Advocacy Group—Focus Group Participants.	Advocacy Representatives Focus Group Guide.	16	1	1

**Jeffrey M. Zirger,**  
*Lead, Information Collection Review Office,  
Office of Public Health Ethics and  
Regulations, Office of Science, Centers for  
Disease Control and Prevention.*  
[FR Doc. 2024–19611 Filed 8–30–24; 8:45 am]  
**BILLING CODE 4163–18–P**

DEPARTMENT OF HEALTH AND  
HUMAN SERVICES

Centers for Disease Control and  
Prevention

[Docket No. CDC–2024–0063]

Meeting of the Advisory Committee to  
the Director (ACD), Centers for Disease  
Control and Prevention

**AGENCY:** Centers for Disease Control and  
Prevention (CDC), Department of Health  
and Human Services (HHS).

**ACTION:** Notice of meeting and request  
for comment.

**SUMMARY:** In accordance with the  
Federal Advisory Committee Act, the  
Centers for Disease Control and  
Prevention (CDC) announces the  
following meeting for the Advisory  
Committee to the Director, Centers for  
Disease Control and Prevention (ACD,  
CDC). This is a hybrid meeting,  
accessible both in person and virtually  
(webcast live via the World Wide Web).  
It is open to the public and limited only  
by the space available.

**DATES:** The meeting will be held on  
October 22, 2024, from 9 a.m. to 3:30  
p.m., EDT (times subject to change).  
The public may submit written  
comments from September 3, 2024  
through October 7, 2024.

**ADDRESSES:** *Meeting address:* CDC  
Roybal Campus, Building 19,  
Auditorium B3, 1600 Clifton Road NE,  
Atlanta, Georgia 30329–4027.

Please note that the meeting location,  
the CDC Roybal Campus, is a federal  
facility and in-person access is limited  
to United States citizens unless prior  
authorizations, taking up to 30 to 60  
days, have been made.

*Registration:* You must register to  
attend this meeting in person. If you  
wish to attend in person, please submit  
a request by email to [ACDDirector@cdc.gov](mailto:ACDDirector@cdc.gov)  
at least 5 business days in  
advance of the meeting. No registration  
is required to view the meeting via the  
World Wide Web. Information for  
accessing the webcast will be available  
at [https://www.cdc.gov/about/advisory-  
committee-director/](https://www.cdc.gov/about/advisory-committee-director/).

*Written comments:* You may submit  
comments, identified by Docket No.  
CDC–2024–0063 by either of the  
following methods below. Do not  
submit comments for the docket by  
email. CDC does not accept comments  
for the docket by email.

- *Federal eRulemaking Portal:*  
<https://www.regulations.gov>. Follow the  
instructions for submitting comments.
- *Mail:* Demetria Gardner, BA,  
Centers for Disease Control and  
Prevention, 1600 Clifton Road NE,

Mailstop H21–10, Atlanta, Georgia  
30329–4027. Attn: Docket number CDC–  
2024–0063.

*Instructions:* All submissions received  
must include the Agency name and  
Docket Number. All relevant comments  
received in conformance with the  
<https://www.regulations.gov>, suitability  
policy will be posted without change to  
<https://www.regulations.gov>, including  
any personal information provided. For  
access to the docket to read background  
documents or comments received, go to  
<https://www.regulations.gov>. Written  
public comments submitted up to 72  
hours prior to the ACD meeting will be  
provided to ACD members before the  
meeting. Written comments received in  
advance of the meeting will be included  
in the official record of the meeting.

**FOR FURTHER INFORMATION CONTACT:**  
Demetria Gardner, BA, Office of the  
Chief of Staff, Centers for Disease  
Control and Prevention, 1600 Clifton  
Road NE, Mailstop H21–10, Atlanta,  
Georgia 30329–4027, Telephone: (770)  
488–4745; Email Address: [ACDDirector@cdc.gov](mailto:ACDDirector@cdc.gov).

**SUPPLEMENTARY INFORMATION:**  
*Purpose:* The Advisory Committee to  
the Director, CDC, shall (1) make  
recommendations to the Director  
regarding ways to prioritize the  
activities of the agency in alignment  
with the CDC Strategic Plan required  
under section 305(c); H.R. 2617–1252;  
(2) advise on ways to achieve or  
improve performance metrics in relation  
to the CDC Strategic Plan, and other  
relevant metrics, as appropriate; (3)

provide advice and recommendations on the development of the Strategic Plan, and any subsequent updates, as appropriate; (4) advise on grant, cooperative agreements, contracts, or other transactions, as applicable; (5) provide other advice to the Director, as requested, to fulfill duties under sections 301 and 311; and (6) appoint subcommittees. The committee recommends ways to prioritize CDC's activities, improve results, and address health disparities. It also provides guidance to help CDC work more effectively with its various private and public sector constituents to make health protection a practical reality.

**Matters to be Considered:** The agenda will include an update on priorities from the CDC Director, discussions on strategic science and impact, artificial intelligence, childhood immunization coverage and efforts to address lagging rates, global update, and updates from the ACD Data and Surveillance Workgroup and the Communications and Public Engagement Workgroup. Agenda items are subject to change as priorities dictate.

#### Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

**Written Public Comment:** The docket will be opened to receive written comments on September 3, 2024 through October 7, 2024.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other

committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2024–19623 Filed 8–30–24; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews; Cancellation of Meeting

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This is to notify the public that the July 30, 2024, meeting of the Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews is cancelled.

**FOR FURTHER INFORMATION CONTACT:**

Rashaun Roberts, Ph.D., National Institute for Occupational Safety and Health, CDC, 1090 Tusculum Avenue, Mailstop C–24, Cincinnati, Ohio 45226, Telephone: (513) 533–6800, Toll Free 1(800) CDC–INFO, Email: [ocas@cdc.gov](mailto:ocas@cdc.gov).

**SUPPLEMENTARY INFORMATION:** Notice is hereby given of a change in the meeting of the Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews (ABRWH, SPR). The meeting was announced in the **Federal Register** on May 17, 2024, Volume 89, Number 97, page 43404. This meeting is being canceled in its entirety. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2024–19622 Filed 8–30–24; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC–2024–0064; NIOSH 248–L]

#### Meeting of the World Trade Center Health Program Scientific/Technical Advisory Committee

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the World Trade Center Health Program Scientific/Technical Advisory Committee (STAC). This virtual meeting is open to the public. Time will be available for public comment.

**DATES:** The meeting will be held on September 23, 2024, from 11 a.m. to 3 p.m., EDT.

Written public comments must be received by September 23, 2024, at 11:59 p.m., EDT. Members of the public who wish to address the STAC during the oral public comment session must sign up to speak by September 16, 2024, at the email address provided in the Procedure for Oral Public Comment section below.

**ADDRESSES:** This is a virtual meeting conducted via Zoom. The public is welcome to follow the proceedings via YouTube Live at the following link: <https://youtube.com/live/7Pokfh4kcsc?feature=share>. No registration is required. For additional information, please visit the World Trade Center Health Program website at [https://www.cdc.gov/wtc/stac\\_meeting.html](https://www.cdc.gov/wtc/stac_meeting.html).

You may submit comments, identified by Docket No. CDC–2024–0064; NIOSH 248–L by either of the methods listed below. CDC does not accept comments by email.

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments.
- **Mail:** Ms. Sherri Diana, NIOSH Docket Office, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1090 Tusculum Avenue, Mailstop C–34, Cincinnati, Ohio 45226. Attn: Docket No. CDC–2024–0064; NIOSH 248–L.

**Instructions:** All submissions received must include the Agency name and docket number (CDC–2024–0064; NIOSH 248–L). The docket will close on